Combining Eyenovia's Optejet dispensing system with Betaliq's EyeSol medication delivery mechanism, the purchase would create ...

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology ...

Eyenovia on Thursday said it has signed a non-binding letter of intent to combine with clinical-stage pharmaceutical company Betaliq in an all-stock reverse merger. Eyenovia said Betaliq investors ...

Eyenovia, Inc. has announced a non-binding letter of intent for a potential reverse merger with Betaliq, Inc., which focuses on glaucoma treatments. If the merger is successful, it would create a ...

(RTTNews) - Eyenovia, Inc. (EYEN) has signed a non-binding letter of intent for a potential reverse merger with Betaliq, Inc., a clinical-stage pharmaceutical company focused on glaucoma treatments.

Eyenovia (EYEN), has entered into a non-binding letter of intent contemplating a potential reverse merger transaction with Betaliq, a clinical ...

Shares of Eyenovia (NASDAQ:EYEN) traded lower on Thursday after the ophthalmic product developer announced a non-binding agreement to seek a reverse merger with Betaliq, Inc., a privately held ...

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet ® device ...

Shares of Eyenovia (NASDAQ:EYEN) traded lower on Thursday after the ophthalmic product developer announced a non-binding agreement to seek a reverse merger with Betaliq, Inc., a privately held ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products ...